Patricia Leckman Sells 2,370 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Illumina Price Performance

Shares of ILMN traded up $3.58 during midday trading on Wednesday, hitting $120.09. 2,616,649 shares of the company traded hands, compared to its average volume of 2,296,889. The stock has a 50-day moving average of $136.77 and a 200-day moving average of $116.89. Illumina, Inc. has a one year low of $68.70 and a one year high of $155.53. The firm has a market cap of $18.36 billion, a P/E ratio of 22.03, a PEG ratio of 2.23 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. Illumina’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Illumina

Hedge funds and other institutional investors have recently modified their holdings of the company. Next Capital Management LLC purchased a new position in Illumina during the 2nd quarter valued at about $341,000. Generali Asset Management SPA SGR increased its position in Illumina by 51.6% during the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock valued at $2,113,000 after buying an additional 7,574 shares in the last quarter. Andra AP fonden increased its position in Illumina by 426.3% during the 2nd quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after buying an additional 83,017 shares in the last quarter. Aaron Wealth Advisors LLC raised its stake in Illumina by 342.6% during the third quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock valued at $995,000 after buying an additional 8,109 shares during the last quarter. Finally, Douglas Lane & Associates LLC boosted its holdings in Illumina by 6.6% in the third quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company’s stock worth $29,214,000 after acquiring an additional 18,914 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ILMN shares. Stifel Nicolaus lifted their target price on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Canaccord Genuity Group upped their target price on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Barclays lifted their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Finally, Evercore set a $150.00 target price on Illumina in a research note on Friday, February 6th. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $127.94.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.